T cell, mouse, stim

Export

lymphocyte isolated from mouse spleen; pre-stimulated

Cell Type:
T Cell
Tissue Origin:
blood
Species:
mouse
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Recommended Media

TheraPEAK® X-VIVO®

TheraPEAK® X-VIVO® Media is a high-performing media series providing nutritionally adequate and balanced environments for a variety of hematopoietic cells including: 

  • T Cells
  • CAR-T cells
  • Peripheral blood lymphocytes (PBL)
  • Tumor infiltrating lymphocytes (TIL)
  • Human monocytes and macrophages
  • Lymphokine-activated killer cells (LAK)
  • Hematopoietic stem cells (HSCs)
  • Dendritic cells (DCs) 

Our scalable media are widely cited in scientific publications and proven to reliably work in many cell therapy applications around the world, from research stages to clinical trials to FDA-approved cell therapies. TheraPEAK® Products are manufactured according to GMP standards and can be safely and confidently used in your clinical processes. Our manufacturing sites are FDA registered with an ISO 13485 certified quality management system. 


There are two main versions of this media.

TheraPEAK® X-VIVO® 10 Media are  optimized for slower growing, less mature cells, such as hematopoietic stem cells

TheraPEAK® X-VIVO® 15 Media are most appropriate for rapidly growing cells, specifically cells of the immune system

TheraPEAK® X-VIVO® 10 Media and 15 Media are also available with recombinant transferrin instead of native human transferrin

Please note: X-VIVO™ 20 is currently available as an RUO grade catalog item. 

Storage: 2-8C, protect from light.

Catalog Offerings:

TheraPEAK® X-VIVO® Medium with native transferrin

Cat. No. NA

Cat.CCat. No. EU

Product

Size

BP04-743Q                            

 

           BEBP04-743Q

TheraPEAK® X-VIVO® 10 Medium without gentamicin and phenol red, contains native transferrin

1 L bottle

BP04-744Q

 

BEBP04-744Q

TheraPEAK® X-VIVO® 15 Medium with L-glutamine, without gentamicin and phenol red, contains native transferrin

1 L bottle

08-879H

08-879P1

 

BE08-879H

BE08-879P1

TheraPEAK® X-VIVO® 15 Medium with L-glutamine, without gentamicin and phenol red, contains native transferrin

5 L bag

1 L bag

TheraPEAK™ X-VIVO™ Medium with recombinant transferrin

Cat. No. NA

Cat. No. EU

Product

Size

N/A

BEBP02-055Q

TheraPEAK® X-VIVO® 10 Medium with L-glutamine, without gentamicin or phenol red, contains recombinant transferrin

1 L bottle

BP02-054Q

BP02-054P1

BEBP02-054Q

BEBP02-054P1

TheraPEAK® X-VIVO® 15 Medium with L-glutamine, without gentamicin and phenol red, contains recombinant transferrin

1 L bottle

1 L bag

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
P3 DN-100 2e5 77% 33% Plasmid (general) 0.4 µg 20 µl 4D X-Unit

Citations (19)

Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis
Categories:
Primary Cells and Media, Transfection, Cell Lines and Primary Cancer Cells 
Authors:
Dettmer-Monaco V, Weißert K, Ammann S, Monaco G, Lei L, Gräßel L, Rhiel M, Rositzka J, Kaufmann MM, Geiger K, Andrieux G, Lao J, Thoulass G, Schell C, Boerries M, Illert AL, Cornu TI, Ehl S, Aichele P, Cathomen T 
In:
J Allergy Clin Immunol (2023) S0091: 6749(23)00989-2 
An evolved AAV variant enables efficient genetic engineering of murine T cells
Categories:
Primary Cells and Media, Transfection 
Authors:
Nyberg WA, Ark J, To A, Clouden S, Reeder G, Muldoon JJ, Chung JY, Xie WH, Allain V, Steinhart Z, Chang C, Talbot A, Kim S, Rosales A, Havlik LP, Pimentel H, Asokan A, Eyquem J 
In:
Cell (2023) 186(2): 446-460 
Structural surfaceomics reveals an AML-specific conformation of integrin ß2 as a CAR T cellular therapy target
Categories:
Primary Cells and Media, Transfection, Cell Lines and Primary Cancer Cells 
Authors:
Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP 
In:
Nature (2023) 11: 1592-1609 
Naïve Primary Mouse CD8+ T Cells Retain In Vivo Immune Responsiveness After Electroporation-Based CRISPR/Cas9 Genetic Engineering
Categories:
Transfection, Cell Lines and Primary Cancer Cells 
Authors:
Pfenninger P, Yerly L, Abe J 
In:
Frontiers in Immunology (2022) 13: 777113 
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Categories:
Transfection 
Authors:
Giuffrida L, Sek K, Henderson MA, Lai J, Chen AXY, Meyran D, Todd KL, Petley EV, Mardiana S, Mølck C, Stewart GD, Solomon BJ, Parish IA, Neeson PJ, Harrison SJ, Kats LM, House IG, Darcy PK, Beavis PA 
In:
Nat Commun. (2021) 12(1): 3236 
ALCAM Mediates DC MigrationThrough Afferent Lymphatics andPromotes Allospecific ImmuneReactions
Categories:
Serum-free and Speciality Media 
Authors:
Ann-Helen Willrodt, Ann-Charlott Salabarria, Philipp Schineis, Desislava Ignatova,Morgan Campbell Hunter, Martina Vranova, Alexandra M. Golding-Ochsenbein,Elena Sigmund, Annatina Romagna, Verena Strassberger, Marina Fabbi,Silvano Ferrini , Claus Cursiefen, Dario Neri, Emmanuella Guenova, Felix Bock andCornelia Halin 
In:
Frontiers in Immunology (2019) 10: 759 
Ribonucleoprotein Transfection for CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells.
Categories:
Primary Cells and Media, Transfection 
Authors:
Oh SA, Seki A, Rutz S.  
In:
Curr Protoc Immunol (2019) 124(1): e69 
Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery.
Categories:
Primary Cells and Media, Transfection 
Authors:
Ito M, Komai K, Mise-Omata S, Iizuka-Koga M, Noguchi Y, Kondo T, Sakai R, Matsuo K, Nakayama T, Yoshie O, Nakatsukasa H, Chikuma S, Shichita T, Yoshimura A. 
In:
Nature (2019) 565 (7738): 246-250 
Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.
Categories:
Primary Cells and Media, Transfection 
Authors:
Seki A, Rutz S. 
In:
J Exp Med (2018) 215(3): 985-997 
Interferon regulatory factor (IRF) 3 is critical for the development of experimental autoimmune encephalomyelitis
Categories:
Serum-free and Speciality Media 
Authors:
Fitzgerald DC, O'Brien K, Young A, Fonseca-Kelly Z, Rostami A, Gran B. 
In:
Journal of Neuroinflammation (2014) 11: 130 
Prostaglandin E2 promotes Th1 differentiation via synergistic amplification of IL-12 signalling by cAMP and PI3-kinase.
Categories:
Transfection 
Authors:
Yao C1, Hirata T, Soontrapa K, Ma X, Takemori H, Narumiya S. 
In:
Nat Commun. (2013) 4: 1685 
Proteoglycan-Induced Arthritis and Recombinant Human Proteoglycan Aggrecan G1 Domain–Induced Arthritis in BALB/c Mice Resembling Two Subtypes of Rheumatoid Arthritis
Categories:
Serum-free and Speciality Media 
Authors:
Tibor T. Glant, Marianna Radacs, Gyorgy Nagyeri, Katalin Olasz, Anna Laszlo, Ferenc Boldizsar, Akos Hegyi, Alison Finnegan, and Katalin Mikecz  
In:
Rheumatology (2011) 63: 5 
Syndecan-4 Mediates the Coinhibitory Function of DC-HIL on T Cell Activation
Categories:
Transfection 
Authors:
Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K 
In:
J Immunol (2007) 179(9): 5778-84 
Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-gamma
Categories:
Transfection 
Authors:
Schoenborn JR, Dorschner MO, Sekimata M, Santer DM, Shnyreva M, Fitzpatrick DR, Stamatoyonnapoulos JA, Wilson CB 
In:
Nat Immunol (2007) 8(7): 732-42 
Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors
Categories:
Transfection 
Authors:
Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H 
In:
Cancer Res (2007) 67(13): 6451-8 
The lymphocyte function-associated antigen-1 receptor costimulates plasma membrane Ras via phospholipase D2
Categories:
Transfection 
Authors:
Mor A, Campi G, Du G, Zheng Y, Foster DA, Dustin ML, Philips MR 
In:
Nat Cell Biol (2007) 9(6): 713-9 
Regulation of Th2 cell development by Polycomb group gene bmi-1 through the stabilization of GATA3
Categories:
Transfection 
Authors:
Hosokawa H, Kimura MY, Shinnakasu R, Suzuki A, Miki T, Koseki H, van Lohuizen M, Yamashita M, Nakayama T 
In:
J Immunol (2006) 177(11): 7656-64 
Enrichment of regulatory CD4(+)CD25(+) T cells by inhibition of phospholipase D signaling
Categories:
Transfection 
Authors:
Singh N, Seki Y, Takami M, Baban B, Chandler PR, Khosravi D, Zheng X, Takezaki M, Lee JR, Mellor AL, Bollag WB, Iwashima M 
In:
Nat Methods (2006) 3(8): 629-36 
Efficient nonviral gene delivery into primary lymphocytes from rats and mice
Categories:
Transfection 
Authors:
Goffinet C and Keppler OT 
In:
FASEB J (2006) 20(3): 500-2 
+ Show All

Privacy | Legal | About Lonza

© Lonza. All rights reserved.